Skip to main content

Table 2 Multivariate analysis of outcomes based on patient, disease, and transplant characteristics

From: Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia

Variable Grade II–IV, acute GVHD Chronic GVHD Relapse NRM LFS OS GRFS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Donor source
MMUD 1.00   1.00   1.00   1.00   1.00   1.00   1.00  
CBT 1.32 (1–1.74) 0.052 0.94 (0.68–1.3) 0.69 1.35 (1–1.83) 0.05 2.09 (1.46–2.99)  < 0.0001 1.68 (1.34–2.12)  < 0.0001 1.7 (1.33–2.17)  < 0.0001 1.49 (1.21–1.83) 0.0002
Patient age (per 10 years) 1.11 (1.02–1.21) 0.02 1.06 (0.96–1.17) 0.24 0.99 (0.9–1.08) 0.81 1.31 (1.18–1.45)  < 0.001 1.12 (1.05–1.2)  < 0.001 1.19 (1.11–1.28)  < 0.001 1.07 (1.01–1.14) 0.02
Pre-HCT disease status
CR1 1.00   1.00   1.00   1.00   1.00   1.00   1.00  
CR2 1.05 (0.81–1.35) 0.72 1.08 (0.8–1.45) 0.63 1.07 (0.78–1.48) 0.67 1.3 (0.97–1.74) 0.08 1.2 (0.97–1.48) 0.10 1.26 (1.01–1.58) 0.04 1.14 (0.94–1.38) 0.20
Advanced 0.78 (0.57–1.08) 0.13 0.95 (0.61–1.5) 0.84 2.89 (2.19–3.83)  < 0.001 2.03 (1.47–2.8)  < 0.001 2.42 (1.96–2.99)  < 0.001 2.57 (2.07–3.21)  < 0.001 1.81 (1.48–2.21)  < 0.001
Cytogenetics
Good risk 1.00   1.00   1.00   1.00   1.00   1.00   1.00  
Intermediate risk 1.22 (0.75–2) 0.42 0.75 (0.45–1.24) 0.26 1.59 (0.77–3.31) 0.21 0.81 (0.48–1.35) 0.41 1.09 (0.72–1.65) 0.69 1.07 (0.69–1.66) 0.75 0.94 (0.66–1.34) 0.73
Adverse risk 1.37 (0.8–2.34) 0.25 0.69 (0.37–1.26) 0.22 3.78 (1.79–7.98)  < 0.001 0.75 (0.41–1.36) 0.34 1.74 (1.12–2.71) 0.01 1.48 (0.93–2.36) 0.10 1.36 (0.92–1.99) 0.12
Unknown risk 1.32 (0.79–2.19) 0.29 0.88 (0.52–1.5) 0.64 1.92 (0.92–4) 0.08 0.85 (0.5–1.44) 0.54 1.23 (0.81–1.88) 0.33 1.2 (0.77–1.87) 0.42 1.18 (0.82–1.7) 0.36
Donor gender
Male donor 1.00   1.00   1.00   1.00   1.00   1.00   1.00  
Female donor 0.82 (0.67–1.01) 0.06 0.9 (0.7–1.15) 0.40 0.94 (0.74–1.2) 0.62 0.87 (0.69–1.11) 0.26 0.9 (0.76–1.06) 0.22 0.91 (0.76–1.08) 0.29 0.83 (0.71–0.97) 0.02
Conditioning regimen
MAC 1.00   1.00   1.00   1.00   1.00   1.00   1.00  
RIC 0.89 (0.69–1.14) 0.34 0.86 (0.64–1.16) 0.33 1.27 (0.97–1.64) 0.08 0.6 (0.46–0.8)  < 0.001 0.86 (0.71–1.03) 0.10 0.79 (0.65–0.97) 0.02 0.85 (0.71–1.01) 0.06
KPS ≥ 90 0.74 (0.58–0.94) 0.02 1.19 (0.86–1.64) 0.30 0.95 (0.72–1.24) 0.69 0.8 (0.6–1.05) 0.10 0.87 (0.72–1.05) 0.16 0.86 (0.7–1.05) 0.15 0.85 (0.71–1.02) 0.09
Centre (frailty)    < 0.001    < 0.001   0.24   0.03   0.30   0.18   0.10
  1. CBT cord blood transplant, MMUD mismatched unrelated donor, CR complete remission, GVHD graft-versus-host disease, NRM non-relapse mortality, PFS progression-free survival, OS overall survival, GRFS GVHD-relapse-free survival, KPS Karnofsky performance scale, RIC reduced intensity conditioning, MAC myeloablative conditioning, HR hazard ratio, CI confidence interval